Online inquiry

IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3067MR)

This product GTTS-WQ3067MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3067MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3874MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ10470MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ5946MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ13994MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ2851MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ4502MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8003MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ8165MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL036337
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW